Stock Track | BioNTech Plunges 5.59% in Pre-market on Widening Losses, Site Closures and Job Cuts

Stock Track

May 05

BioNTech SE shares plummeted 5.59% in pre-market trading following the release of its first-quarter results and a major restructuring announcement.

The German biotech firm reported a net loss of €531.9 million for Q1 2026, widening from a loss of €415.8 million in the same period last year. Revenue fell sharply to €118.1 million from €182.8 million year-over-year, reflecting the continued decline in COVID-19 vaccine sales.

Concurrently, BioNTech announced it will exit operations at several sites, including CureVac's facilities and its own locations in Idar-Oberstein, Marburg, Tuebingen, and Singapore. The closures are expected to affect approximately 1,860 jobs, with German sites ceasing operations by the end of 2027 and Singapore operations ending in the first quarter of 2027. The company also confirmed the full transfer of its COVID-19 vaccine production to partner Pfizer during 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1116690605"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116690605\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116690605?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-05 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116690605","market":"nz","top_or_hot":-1,"title":"Stock Track | BioNTech Plunges 5.59% in Pre-market on Widening Losses, Site Closures and Job Cuts","media":"Stock Track","content":"<p>BioNTech SE shares plummeted 5.59% in pre-market trading following the release of its first-quarter results and a major restructuring announcement.</p><p>The German biotech firm reported a net loss of €531.9 million for Q1 2026, widening from a loss of €415.8 million in the same period last year. Revenue fell sharply to €118.1 million from €182.8 million year-over-year, reflecting the continued decline in COVID-19 vaccine sales.</p><p>Concurrently, BioNTech announced it will exit operations at several sites, including CureVac's facilities and its own locations in Idar-Oberstein, Marburg, Tuebingen, and Singapore. The closures are expected to affect approximately 1,860 jobs, with German sites ceasing operations by the end of 2027 and Singapore operations ending in the first quarter of 2027. The company also confirmed the full transfer of its COVID-19 vaccine production to partner Pfizer during 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioNTech Plunges 5.59% in Pre-market on Widening Losses, Site Closures and Job Cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioNTech Plunges 5.59% in Pre-market on Widening Losses, Site Closures and Job Cuts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-05 18:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech SE shares plummeted 5.59% in pre-market trading following the release of its first-quarter results and a major restructuring announcement.</p><p>The German biotech firm reported a net loss of €531.9 million for Q1 2026, widening from a loss of €415.8 million in the same period last year. Revenue fell sharply to €118.1 million from €182.8 million year-over-year, reflecting the continued decline in COVID-19 vaccine sales.</p><p>Concurrently, BioNTech announced it will exit operations at several sites, including CureVac's facilities and its own locations in Idar-Oberstein, Marburg, Tuebingen, and Singapore. The closures are expected to affect approximately 1,860 jobs, with German sites ceasing operations by the end of 2027 and Singapore operations ending in the first quarter of 2027. The company also confirmed the full transfer of its COVID-19 vaccine production to partner Pfizer during 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"","article_id":"1116690605","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116690605","pubTimestamp":1777978765,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioNTech SE shares plummeted 5.59% in pre-market trading following the release of its first-quarter results and a major restructuring announcement.The German biotech firm reported a net loss of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"个股追踪|BioNTech盘前暴跌5.59%因亏损扩大、工厂关闭和裁员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"BioNTech SE shares plummeted 5.59% in pre-market trading following the release of its first-quarter results and a major restructuring announcement.The German biotech firm reported a net loss of €531.9 million for Q1 2026, widening from a loss of €415.8 million in the same period last year. Revenue fell sharply to €118.1 million from €182.8 million year-over-year, reflecting the continued decline in COVID-19 vaccine sales.Concurrently, BioNTech announced it will exit operations at several sites, including CureVac's facilities and its own locations in Idar-Oberstein, Marburg, Tuebingen, and Singapore. The closures are expected to affect approximately 1,860 jobs, with German sites ceasing operations by the end of 2027 and Singapore operations ending in the first quarter of 2027. The company also confirmed the full transfer of its COVID-19 vaccine production to partner Pfizer during 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}